Skip to main content
Fig. 3 | Cardiovascular Diabetology

Fig. 3

From: Intravenous ferric carboxymaltose for iron repletion following acute heart failure in patients with and without diabetes: a subgroup analysis of the randomized AFFIRM-AHF trial

Fig. 3

KCCQ-12 OSS and CSS with FCM vs placebo in patients with and without diabetes. KCCQ-12 OSS (A) and CSS (B) with FCM vs placebo in patients with and without diabetes, and (C) interaction of diabetes status with FCM treatment effect at Week 24. mITT population analyzed. *p < 0.05 for FCM vs placebo no diabetes subgroup only (no significant changes were observed in the diabetes subgroup). Error bars are standard error. Estimates are based on a mixed-effect model of repeated measures using an unstructured covariance matrix: change score = baseline score + treatment + visit + treatment × visit + subgroup + subgroup × visit + subgroup × treatment + subgroup × treatment × visit + baseline covariates. CI confidence interval, CSS clinical summary score, FCM ferric carboxymaltose, KCCQ-12 Kansas City Cardiomyopathy Questionnaire, mITT modified intention-to-treat, OSS overall summary score

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840